Daan Gene Valuation
Is 002030 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 002030 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 002030 (CN¥6.45) is trading above our estimate of fair value (CN¥1.71)
Significantly Below Fair Value: 002030 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 002030?
Other financial metrics that can be useful for relative valuation.
| What is 002030's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.8x |
| Enterprise Value/EBITDA | -25.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 002030's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.2x | ||
301047 Sino BiologicalInc | 13.4x | 15.6% | CN¥8.4b |
688105 Nanjing Vazyme Biotech | 7.1x | 23.8% | CN¥9.5b |
688767 Hangzhou Biotest BiotechLtd | 6.1x | n/a | CN¥3.1b |
002038 Beijing SL Pharmaceutical | 10x | n/a | CN¥7.6b |
002030 Daan Gene | 9.7x | n/a | CN¥8.7b |
Price-To-Sales vs Peers: 002030 is expensive based on its Price-To-Sales Ratio (9.7x) compared to the peer average (9.2x).
Price to Earnings Ratio vs Industry
How does 002030's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Sales vs Industry: 002030 is expensive based on its Price-To-Sales Ratio (9.7x) compared to the CN Biotechs industry average (7.4x).
Price to Sales Ratio vs Fair Ratio
What is 002030's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 002030's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.